Rhythm Pharmaceuticals (RYTM) Accumulated Expenses (2016 - 2026)

Rhythm Pharmaceuticals (RYTM) has 11 years of Accumulated Expenses data on file, last reported at $80.0 million in Q1 2026.

• Accumulated Expenses for Q1 2026 came in at $80.0 million, up 34.95% year-over-year; the trailing twelve-month figure through Mar 2026 was $80.0 million (up 34.95% YoY), and the FY2025 annual result was $83.9 million, up 33.83% from the prior year.
• Accumulated Expenses declined to $80.0 million in Q1 2026 per RYTM's latest filing, from $83.9 million in the prior quarter.
• Over five years, Accumulated Expenses peaked at $84.5 million in Q3 2025 and troughed at $25.2 million in Q1 2022.
• A 5-year average of $50.9 million and a median of $48.1 million in 2024 frame the typical range for Accumulated Expenses.
• The sharpest annual moves came in 2022 and 2023: Accumulated Expenses soared 252.43% in 2022, then gained 0.29% in 2023.
• A 5-year view of Accumulated Expenses shows it stood at $32.9 million in 2022, then soared by 46.72% to $48.3 million in 2023, then advanced by 29.83% to $62.7 million in 2024, then jumped by 33.83% to $83.9 million in 2025, then decreased by 4.54% to $80.0 million in 2026.
• Business Quant data shows RYTM's Accumulated Expenses at $80.0 million in Q1 2026, $83.9 million in Q4 2025, and $84.5 million in Q3 2025.